Patient Advocates Decry Florida’s “Discriminatory” Insurance Barriers to Hepatitis C Cures
Health insurers who deny patients access to hepatitis C cures could be violating federal law, explains an April 5 letter from the Alliance for Patient Access and The AIDS Institute to Florida’s insurance commissioner.
FDA’s Second Biosimilar Approval Hints at Random Naming System
The Food and Drug Administration approved the second U.S. biosimilar on Tuesday, clearing the drug for seven different indications.
FDA’s Draft Biosimilar Labeling Guidance Falls Short on Patient Safety Measures
The Food and Drug Administration has released its long-anticipated draft guidance on biosimilar labeling – but the document may leave some health care providers and patient advocates disappointed.
Indiana Tackles Step Therapy
Indiana Governor Mike Pence has signed into law a bill restricting the use of step therapy – following in the footsteps of California, Maryland, New Hampshire and other states that have tackled the issue.
Clinical practice guidelines are intended to optimize patient care, explains a new policy brief from the Institute for Patient Access.
Two months have passed since the World Health Organization released its final proposal on naming biological and biosimilar medications.
New IfPA Policy Brief Explores Clinical Practice Guidelines and Patient Access
Clinical practice guidelines are intended to optimize patient care, explains a new policy brief from the Institute for Patient Access.
Government Recommendations Overshadow Dubious New Report on Prenatal Nutrition
Many pregnant women embrace eating habits that protect and benefit their unborn babies. But their choices can become complicated when claims from unscientific sources clash with regulatory agencies’ clear, established nutrition guidance.
CDC Opioid Guidelines Address Integrated Care but Leave Access Worries Intact
Following a lengthy and controversial process, the Centers for Disease Control and Prevention issued new guidelines Tuesday on prescribing opioids for pain.
Medicare Part B Proposal Raises Patient Access Concerns
The Centers for Medicare and Medicaid Services’ newly proposed rule may reinvent how medications are paid for under Part B, which covers infused or injected medications administered in a clinic or hospital setting.
FDA Aims for More Diverse Clinical Trials
The Food and Drug Administration is on a mission: Make 2016 the year of diversity in clinical trials.
